Acyclic amides (including acyclic carbamates) and their derivatives: salts thereof: meprobamate (INN)

In 2024, acyclic amides (including acyclic carbamates) and their derivatives: salts thereof: meprobamate (inn) trade exhibited strong growth, with global flows reaching $11,406,325 and a three-year compound annual growth rate of +23.1% (five-year: +17.6%). The all-time peak of $52,103,901 was recorded in 2002; the current level is 78% below that high-water mark.

Over the 30-year observation window (1995–2024), 45% of years recorded positive growth, indicating significant cyclicality with frequent contractions. Trend momentum is strengthening (+18.6% acceleration).

The supply side is moderately concentrated (Herfindahl-Hirschman Index 0.180). The three largest exporters — China ($3.7M), Netherlands ($2.9M), and Belgium ($2.7M) — collectively dominate supply flows. The leading exporter has grown at -3.5% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.120). The three largest import markets are Ireland ($2.4M), India ($2.0M), and United States ($1.5M). The largest importing market sources from 7 different supplying countries.

The dominant trade corridor is Belgium → Ireland at $2.2M, representing 91.7% of the importer's total demand.

The volatility score for acyclic amides (including acyclic carbamates) and their derivatives: salts thereof: meprobamate (inn) is 28 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, strong demand tailwinds create a favourable entry environment. A moderately concentrated market rewards differentiated positioning and strategic partner selection.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.